

Please amend the application as follows:

In the Claims

Please amend Claims 35, 88 and 108. Claims 35, 88 and 108 are presented below in amended form. Amendments to the claims are indicated in the attached "Marked Up Version of Amendments" (page i).

B1 C3 35. (Twice Amended) The isolated cell of Claim 34 wherein said antibody or antigen-binding fragment inhibits a cellular response to binding of ligand to said Bonzo in an *in vitro* assay with an IC_{50} of less than about 7 $\mu\text{g/mL}$.

B2 88. (Twice Amended) The test kit of Claim 84 wherein said antibody or antigen-binding fragment is selected from the group consisting of

- a) mAb 4A11, the antibody produced by the hybridoma cell line deposited as ATCC Accession Number PTA-991;
- b) mAb 7A2, the antibody produced by the hybridoma cell line deposited as ATCC Accession Number PTA-992;
- c) mAb 7F3, the antibody produced by the hybridoma cell line deposited as ATCC Accession Number PTA-990;
- d) an antibody which can compete with mAb 4A11, mAb 7A2 or mAb 7F3 for binding to mammalian Bonzo; and
- e) an antigen-binding fragment of a), b), c) or d).

B3 108. (Amended) The antibody or antigen-binding fragment of Claim 107 wherein said antibody or antigen-binding fragment has the epitopic specificity of mAb 7F3, the antibody produced by the hybridoma cell line deposited as ATCC Accession Number PTA-990.